

Monthly statement of total voting rights and shares forming the company's share capital

Article L233-8-II of the French Commercial Code
Article 223-16 of the General Regulations of the AMF (French Financial Markets Authority)

Market: Euronext Paris, Compartment B
ISIN code: FR0012616852

Date	Number of shares outstanding	Total voting rights	
		Total gross ⁽¹⁾	Total net ⁽²⁾
March 31, 2017	18,303,263	18,303,263	18,269,193

- (1) The total number of gross (or "theoretical") voting rights is used as the basis for calculating threshold crossings. In accordance with Article 223-11 of the AMF General Regulations, this number is calculated on the basis of all shares to which voting rights are attached, including those for which voting rights have been suspended.
- (2) The total number of net (or "exercisable at a Shareholders' Meeting") voting rights is calculated without taking into account shares for which voting rights have been suspended. It is released in order to ensure that the public is properly informed, in accordance with the recommendation made by the AMF on 17 July 2007.

About Cerenis Therapeutics: www.cerenis.com

Cerenis Therapeutics is an international biopharmaceutical company dedicated to the discovery and development of innovative therapies for the treatment of cardiovascular and metabolic diseases. Cerenis is developing a portfolio of therapies, including HDL mimetics for patients with HDL deficiency. Since its inception in 2005, the company has been funded by top-tier investors including Sofinnova Partners, HealthCap, Alta Partners, EDF Ventures, Daiwa Corporate Investment, TVM Capital, Orbimed, IRDI/IXO Private Equity and Bpifrance. In March 2015 Cerenis completed an IPO on Euronext raising €53.4m.



Contacts:

Cerenis
Jean-Louis Dasseux
CEO
info@cerenis.com
Tel: +33 (0)5 62 24 09 49

NewCap
Investors relations
Emmanuel Huynh / Louis-Victor Delouvrier
cerenis@newcap.eu
Tel: +33 (0)1 44 71 98 53

NewCap
Media relations
Nicolas Merigeau
cerenis@newcap.eu
Tel: +33 (0)1 44 71 94 98